Toll-like receptors (TLRs) play a fundamental role in innate immunity and provide a link between innate and adaptive responses to an allograft; however, whether the development of acute and chronic allograft rejection requires TLR signaling is unknown. Here, we studied TLR signaling in a fully MHC-mismatched, life-sustaining murine model of kidney allograft rejection. Mice deficient in the TLR adaptor protein MyD88 developed donor antigen-specific tolerance, which protected them from both acute and chronic allograft rejection and increased their survival after transplantation compared with wild-type controls. Administration of an anti-CD25 antibody to MyD88-deficient recipients depleted CD4 + CD25 + FoxP3 + cells and broke tolerance. In addition, defective development of Th17 immune responses to alloantigen both in vitro and in vivo occurred, resulting in an increased ratio of Tregs to Th17 effectors. Thus, MyD88 deficiency was associated with an altered balance of Tregs over Th17 cells, promoting tolerance instead of rejection. This study provides evidence that targeting innate immunity may be a clinically relevant strategy to facilitate transplantation tolerance.
The success of transplantation is limited by the requirement to use lifelong immunosuppression to prevent allograft rejection. Current immunosuppression strategies are both incompletely effective at preventing acute and chronic rejection 1,2 and result in complications, which limit graft and patient survival. [3] [4] [5] Immunosupression primarily targets the adaptive alloimmune response; however, recent data have revealed a likely requirement for innate immunity in allograft rejection in both mediating inflammation and promoting an effective adaptive alloimmune response. [6] [7] [8] Toll-like receptors (TLRs) are innate immune receptors expressed by a variety of immune cell types and a number of nonimmune cells, including kidney tubular epithelial cells 9 and glomerular endothelial cells. 10, 11 TLRs recognize pathogen-associated molecular patterns that are present on microorganisms and also recognize endogenous ligands released from damaged tissue. 9 All TLRs, except TLR3, can signal through an adaptor molecule, myeloid differentiation primary response gene (88) (MyD88), which leads to nuclear translocation of NF-kB, with consequent upregulation of proinflammatory cytokines (TNF-a and IL-6) and chemokine (C-C motif) ligand 2 (CCL2); this upregulation contributes to local inflammation and leukocyte accumulation.
Engagement of TLRs initiates an innate immune response that subsequently promotes the development of effective adaptive immunity 12 through activation of antigen-presenting cells (APCs), including upregulation of MHC class II antigens, costimulatory molecules, chemokines, and cytokines (e.g., IL-6, IL-12, and IL-23). After organ transplantation, these TLRdriven innate immune responses are important for the promotion of ischemia reperfusion injury (IRI) 9 and the initiation of adaptive alloimmunity, which causes acute and chronic rejection.
Significant and nonredundant roles have been shown for TLR2 and TLR4 signaling in kidney IRI. 9, 13, 14 We previously reported that IRI resulted in upregulation of TLR4 and its endogenous ligands high-mobility group protein B1(HMGB1), hyaluronan, and biglycan within the kidney and that TLR4 activation through the MyD88 pathway is a key mediator of kidney IRI. 9 We subsequently showed potential for blockade of the endogenous TLR ligand HMGB1 through TLR4 signaling to prevent kidney IRI. 15 In humans, the presence of a hypofunctioning TLR4 polymorphism has been associated with protection from IRI, manifesting as a reduced incidence of delayed graft function after kidney transplantation. 16 Given the importance of TLR/MyD88 signaling in kidney IRI, the association between reduced TLR4 function and improved outcomes in human kidney transplantation, and the emerging roles for innate immunity in modulating adaptive immunity, we hypothesized that TLR signaling through MyD88 is required for the development of kidney allograft rejection. In the current set of experiments, we compared MyD88 2/2 and wild-type (WT) mice after receipt of lifesustaining fully MHC-mismatched kidney allografts. We herein present data that show how the absence of TLR signaling by MyD88 protected mice from acute and chronic rejection through the development of donor-specific tolerance.
RESULTS

Absence of MyD88 Signaling Prolongs Kidney Allograft Survival
We transplanted BALB/c.MyD88 2/2 (H2-K d ) kidneys into C57BL/6.MyD88 2/2 recipients (H2-K b ) as MyD88 2/2 allografts. Survival to 100 days was observed in all isografts. WT mice rejected their WT allografts with a mean graft survival of 40 days, whereas MyD88 2/2 allografts displayed prolonged survival ( Figure 1A ). When MyD88 was absent from recipients, five of five allografts survived to 100 days ( Figure 1B) . When only the allograft was MyD88-deficient, survival was modestly prolonged over WT allografts; however, only three of seven recipients survived to 100 days ( Figure 1B ).
Absence of MyD88 Signaling Protects against Acute Kidney Rejection at Day 14
Significant kidney dysfunction in WT allografts was evident and reflected by a tripling of serum creatinine compared with isografts ( Figure 2A ). Kidney function was preserved in MyD88 2/2 and recipient MyD88 2/2 donor MyD88 +/+ allografts equally, whereas only partial preservation of function was seen in recipient MyD88 +/+ donor MyD88 2/2 allografts compared with WT allografts (Figure 2A and Supplemental Figure 1A ).
WT allografts exhibited severe tubulitis compared with isografts. Tubulitis was present in MyD88 2/2 allografts and allografts where either donor or recipient was MyD88 2/2 , although it was significantly diminished compared with WT allografts ( Figure 2B and Supplemental Figure 1B) .
Substantial infiltration of CD4 + and CD8 + cells was evident in WT allografts versus isografts (P,0.001) ( Figure 2C ). CD8 + , although not CD4 + , cell infiltration was attenuated in MyD88 2/2 allografts ( Figure 2C ). Extensive macrophage (CD68 + ) accumulation was evident in WT allografts compared with isografts; however, this accumulation was markedly diminished in MyD88 2/2 allografts ( Figure 2C ).
Reduced Expression of Proinflammatory and Th1
Cytokines and Cytotoxic Molecules in MyD88
Allografts at Day 14 WT allografts showed strong upregulation of proinflammatory cytokines (TNF-a, IL-6, and TGF-b) and cytokines (IFN-g, IL-4, and IL-17) compared with isografts ( Figure 2D ). All proinflammatory cytokines and IFN-g were reduced in MyD88
allografts compared with WT allografts ( Figure 2D ), whereas upregulation of IL-4 was of a similar magnitude to the magnitude in WT allografts. MyD88 2/2 allografts showed a nonsignificant trend to reduced expression of IL-17 compared with WT allografts (P=0.06) ( Figure 2D ). Cytotoxic molecules (perforin, granzyme, and inducible nitric oxide synthase) are mediators of kidney damage during acute rejection. All were upregulated in WT allografts compared with isografts but attenuated in the absence of MyD88 ( Figure 2D ).
MyD88 Deficiency Is Protective against Chronic
Allograft Injury at Day 100 Post-Transplantation By day 100 post-transplantation, surviving WT mice had developed significant kidney allograft dysfunction, which was evidenced by increased serum creatinine and proteinuria for WT allografts versus isografts ( Figure 3, A and B) . Kidney function remained normal in MyD88 2/2 allografts and was comparable with kidney function of isografts. Proteinuria in MyD88 2/2 allograft mice was similar to isografts and significantly less than WT allografts ( Figure 3B ).
WT allografts developed severe glomerulosclerosis, interstitial fibrosis, and tubular atrophy, whereas these changes were absent in isografts and attenuated in MyD88 2/2 allografts ( Figure 3 ). To verify interstitial fibrosis, we stained collagen and a-smooth muscle actin (a-SMA). The expression of interstitial collagen and a-SMA was significantly higher in WT allografts versus isografts and significantly reduced in MyD88 2/2 allografts ( Figure 3C ). Significant CD4 + and CD8 + cell accumulation was evident in WT allografts compared with isografts (P,0.05), with a modest reduction in MyD88 2/2 mice compared with WT ( Figure 3C ). There was a significant increase in CD68 + in WT allografts compared with isografts (P,0.01), which was attenuated in MyD88 2/2 allografts ( Figure 3C ). There was no significant difference between isografts and MyD88 2/2 mice.
In human kidney transplantation, complement split product C4d deposition in peritubular capillaries (PTCs) is a marker of antibody-mediated rejection and is associated with development of transplant glomerulopathy. Prominent C4d staining was present diffusely in almost all cross-sections of PTCs, with a bright, broad linear pattern in WT allografts ( Figure 3C ). Fluorescence intensity of C4d deposition in PTCs was significantly reduced in MyD88 2/2 allografts. Consistent with this result, WT allograft recipients exhibited higher titers of donor-specific antibody, both IgG2a and IgG1 subclasses, compared with MyD88 2/2 allografts (Supplemental Figure 2) .
Absence of MyD88 Signaling Results in Reduced mRNA Expression of Proinflammatory and Th1
Cytokines, Chemokines, and Fibrosis-Related Genes Expression of proinflammatory cytokines (TNF-a, IL-6, and IL-1b) was upregulated in WT allografts compared with isografts (P,0.01) and partially reduced in MyD88 2/2 allografts compared with WT ( Figure 4 ). IFN-g mRNA was increased in WT allografts compared with isografts (P,0.001) but not MyD88 2/2 allografts ( Figure 4 ). IL-4 mRNA expression in WTand MyD88 2/2 allografts was higher than in isografts (Figure 4) . IL-17 expression was upregulated in WTallografts compared with isografts but not MyD88 2/2 allografts (P=0.08) (Figure 4) . Expression of chemokines (CCL2, chemokine [C-X-C motif] ligand 9 [CXCL9], and CXCL10) was significantly higher in WT mice compared with isografts (P,0.05) (Figure 4 2/2 recipients retained normal kidney function, which was evidenced by normal serum creatinine (13.363.1 mmol/L) when euthanized at day 180 after skin grafting. Consistent with donor antigen-specific tolerance, MyD88 2/2 splenocytes harvested from an MyD88 2/2 allograft acceptor at day 100 after kidney transplantation stimulated with donor-matched allogeneic spleen cells produced significantly less IFN-g than similarly stimulated WT splenocytes from a WT allograft acceptor as assessed by ELISPOT ( Figure 5C ). Figure 6A ). Administration of anti-CD25 mAb to WT allograft recipients did not alter rejection kinetics ( Figure 6B ).
We next sought to determine whether tolerance was trans- Figure 6C ). 
Increased Ratio of Tregs/Th17 Teffs Cells in MyD88
2/2
Allografts
There was a significant increase in CD4 + FoxP3 + cells as a percentage of total CD4 + splenocytes obtained from WT allograft recipients, and to a greater extent, there was a significant increase in MyD88 2/2 allograft recipients compared with isograft recipients at day 14 post-transplant ( Figure 7A ). There was no significant difference in the percentages of CD4 + and CD8 + splenocytes producing either IL-17 or IFN-g obtained from WT or MyD88 2/2 allograft recipients (Supplemental Figure 3) .
We isolated CD4 + and CD8 + lymphocytes from kidney grafts at day 14. CD4 + FoxP3 + Tregs were significantly increased in MyD88 2/2 allografts compared with WT allografts ( Figure 7A ). The percentages of CD4 + and CD8 + cells producing IL-17 obtained from WT allografts were significantly higher than the percentages from MyD88 2/2 allografts (Figure 7B ), whereas the percentage of T cells producing IFN-g was similar in both ( Figure 7C ).
To confirm the role of Th17 in kidney allograft rejection in our model, we transplanted BALB/c.IL17
2/2 allografts displayed prolonged survival compared with WT allografts (P,0.05; data not shown).
Absence of MyD88 Impairs Alloreactive Th17 Development, Resulting in an Increased Ratio of Tregs/ Th17 Teffs Cells in Mixed Lymphocyte Cultures
We examined whether the absence of MyD88 would produce less IL-6 and consequently, an increased ratio of Treg/Th17 cells in an alloreactive mixed lymphocyte culture under conditions promoting either iTreg or Th17 differentiation. Figure 8C ). These results suggest that absence of MyD88 impairs alloreactive Th17 differentiation, resulting in an increased ratio of Tregs/Th17 Teffs in the alloreactive culture system in vitro.
MyD88
2/2 Mice Exhibit Fewer Donor-Specific Th17
Immune Responders as Assessed by ELISPOT To investigate whether MyD88 2/2 -tolerant mice generated fewer donor-specific Th17 cells, we measured T cell production of IFN-g, IL-4, and IL-17 in response to allostimulation by ELISPOT assay. WT and MyD88 2/2 splenocytes, primed and stimulated with allogeneic cells, produced higher numbers of donor-reactive IFN-g spots than splenocytes similarly stimulated with syngenic or third-party (B10Br) cells ( Figure 9A ). IL-4 production was not different between WT and MyD88 2/2 spleen cells ( Figure 9B ). The number of IL-17-producing cells was significantly greater in WT compared with MyD88 2/2 splenocytes after donor allostimulation ( Figure 9C ), with no significant difference after stimulation by either isogenic or third-party control cells.
DISCUSSION
IRI is an inevitable consequence of kidney implantation, and it leads to rapid activation of an innate immune response causing kidney injury. In the present study, we found that expression of both TLR2 and -4 and their endogenous ligands, including HMGB1, hyaluronan, and biglycan, was similarly increased in kidney grafts after transplantation (Supplemental Figure 4 ). These results, taken together with observational studies showing TLR4 and ligand upregulation within hours of human transplantation, 16 suggest that TLR activation is a mediator of the innate immune response within the newly transplanted kidney.
Modulation of the graft microenvironment by this early innate response may be a prerequisite for the full development of adaptive alloimmunity and subsequent allograft rejection.
In an allosensitized mouse model, allografts were acutely rejected in the presence of inflammation caused by ischemia reperfusion but not in its absence. 6 In humans, observational studies have shown improved outcomes of lung and kidney allografts in patients with hypofunctioning TLR4 polymorphisms. [17] [18] [19] Experimental work has shown that, although the absence of MyD88 signaling was sufficient to prevent minor MHC mismatched skin graft rejection, 20 survival of fully mismatched allogeneic skin and heart transplants was not prolonged. 21 A recent study reported that recipient MyD88 contributes to chronic graft dysfunction. 22 Against this background, the importance of MyD88 signaling in the development of kidney allograft rejection was not fully understood. The current study found that mice genetically deficient in MyD88 developed donor-specific tolerance across a full MHC mismatch that was robust, which was shown by acceptance of donor-matched skin but rejection of thirdparty grafts. Our observations that CD25 depletion was sufficient to break tolerance and that tolerance was associated with impaired Th17 responses to alloantigen provide new evidence highlighting the extent to which adaptive alloimmunity may be controlled by the innate immune system.
TLRs can trigger activation of several arms of the adaptive immune response, generating effectors including Ig, Th1 and Th17 CD4 + effector T cells, and CD8 + effector T cells. The MyD88 pathway is known to be important in generating Th1 responses. 12 Studies in allotransplant models seem partially consistent with this data. Gene expression of IFN-g but not IL-4 was diminished in draining lymph nodes retrieved from MyD88 2/2 skin allograft recipients compared with WT recipients. 20 In the present study, we found that IFN-g mRNA expression was significantly reduced in MyD88 2/2 allografts compared with WT allografts. However, IL-4 mRNA expression was comparable, and CD4 + and CD8 + T cells isolated from WT and MyD88 2/2 kidney allografts at day 14 post-transplant contained comparable numbers of IFN-g-producing T cells. Consistent with this result, recent experimental data in transplantation has provided evidence that MyD88 signaling is not critical for allogeneic dendritic cells (DCs) or APCs to activate alloprimed T cells, 21 although MyD88 deficiency led to a reduction in allogeneic T cell priming and consequent Th1 immunity in a skin transplant model. 21 Although IFN-g is an essential component of Th1-driven immune responses, it is also a critical cytokine in tolerance. IFN-g has been shown to act as a protective factor against the onset of experimental autoimmune encephalomyelitis, 23 and IFN-g is specifically required for the induction of tolerance to alloantigens in several transplantation models. [24] [25] [26] [27] IFN-g seems to be required for the generation and function of allospecific Tregs during the development of operational tolerance to donor alloantigens in vivo. 28 30 Activation of TLRs may regulate the development of Th17 cells. TLR signaling through MyD88 leads to the production of proinflammatory cytokines including IL-6, a potent Th17 differentiation cytokine. Naïve T cells in the presence of IL-6 combined with TGF-b differentiate into Th17. Th17 cells are important for the clearance of pathogens but have also been found to have pathogenic roles in autoimmune and inflammatory diseases. [31] [32] [33] [34] [35] Evidence has emerged that Th17 cells are active in the process of IRI and allograft rejection. IL-17A 2/2 and IL-17R 2/2 mice were found to be protected from kidney IRI 36 and elevation of IL-17 mRNA, and protein has been identified in the early stages of rat and human kidney allograft rejection, suggesting a role for Th17 cells, particularly in the initiation of rejection. [37] [38] [39] It has been shown, using mice deficient in the Th1-specific transcription factor T-bet, that Th17 cells can mediate cardiac allograft rejection 40 and are responsible for costimulation blockade-resistant allograft rejection. 41, 42 In the current study, we found that WT allografts expressed significantly higher amounts of IL-6 and TGF-b than MyD88 2/2 allografts, and IL-17 mRNA was significantly increased in WTallografts (Supplemental Figure 5) 46 and nTregs, in the presence of IL-6, can themselves differentiate into Th17 cells. 47 In transplantation, the activation of innate immunity through TLR signaling allografts compared with WT allografts and not significantly different to isografts (*P,0.05). (C) Illustration of representative sections of the histologic changes on PAS, PSR, and immunochemistry staining for a-SMA, CD4, CD8, CD68, and CD11c and fluorescence staining for C4d in isografts, WT, and MyD88 2/2 allografts. Significant glomerulosclerosis, interstitial fibrosis, and tubular atrophy were evident in WT allografts compared with isografts (P,0.01) and MyD88 2/2 allografts (**P,0.01). WT allografts had significantly higher expression of collagen than isografts (P,0.01) and MyD88 2/2 allografts (P,0.01). Significant a-SMA staining was evident throughout the cortex of WT allografts but largely absent in isografts and MyD88 2/2 allografts (**P,0.01). Interstitial infiltrates in the allograft at day 100 after kidney transplant. The CD4 + and CD8 + infiltrates were significantly increased in WT allografts and to a lesser degree, in MyD88 2/2 allografts compared with isografts (P,0.05). MyD88 2/2 allografts had significantly reduced CD68 + cell accumulation compared with WT allografts.
Prominent C4d staining was present diffusely in peritubular capillaries in WT allografts at day 100 post-transplant, whereas fluorescence intensity of C4d deposition was significantly diminished in MyD88 2/2 allografts (***P,0.001). Data are presented as mean 6 SD (n=5 for isografts; n=8 for each allograft group). 49 Indeed, our in vitro data also showed that absence of MyD88 impairs Th17 development and results in an increased ratio of Tregs/Th17effs in an alloreactive culture in vitro.
TLR activation may prevent experimental transplantation tolerance. Peritransplant infection triggers TLR signaling, which abrogates transplantation tolerance induced by costimulatory blockade. Administration of TLR agonists abrogated costimulation blockade-induced prolongation of skin allograft survival [50] [51] [52] and prevented cardiac allograft acceptance, which was associated with impaired intragraft recruitment and function of CD4 + FoxP3 + regulatory T cells. 50, 52 Conversely, impaired innate responses in MyD88-deficient recipients promoted costimulation blockade-induced allograft acceptance by the impairment of DC production of IL-6, reduced T cell activation, and enhanced T cell suppression mediated by CD4 + CD25 + Tregs. 53 We found a high frequency of CD4 +
FoxP3
+ cells within spleens and kidney allografts of tolerant 2/2 recipients in this model. One limitation of our data is the lack of specificity of MyD88 for the TLRs, because both IL-1 and -18 can also signal through MyD88. Studies using caspase-1-deficient recipients that cannot activate MyD88 through IL-1 and -18 have shown that TLR-MyD88 signaling is critical for the rejection of minor mismatched skin allografts 20 and costimulation blockade-induced skin allograft acceptance. 53 We previously showed that IL-18 does not impact on the development of kidney allograft rejection in our model. 54 Thus, we believe that TLR-mediated activation of the MyD88 pathway is critical in our model, and the findings are unlikely to be attributable to either IL-1 or -18.
In conclusion, our study has showed that, in the absence of MyD88, mice developed donor-specific kidney allograft tolerance, which was associated with impairment of Th17 and Th1 effectors, resulting in an increased ratio of Tregs over Th17 cells. Our data imply that inhibiting innate immunity may be a potential clinically relevant strategy to facilitate transplantation tolerance. 
CONCISE METHODS
Animals
Survival Experiment
To determine the importance of MyD88 signaling in allograft rejection, MyD88 2/2 allografts (n=17), donor MyD88 2/2 allografts (n=7), and recipient MyD88 2/2 allografts (n=5) were compared with WT allografts (n=31) and isografts (n=6). For those recipients surviving to day 150, a proportion of MyD88 2/2 allografts (n=4) and WT allografts (n=4) received full-thickness skin grafts from three sources: BALB/c (kidney donor-matched skin allograft), C57BL/6 (syngeneic), and B10Br (third-party allografts). Grafts were observed regularly for signs of rejection to at least day 100. 
Time Course Study
To examine intragraft events and mechanisms, groups of WT allografts and MyD88 2/2 allografts were killed early (day 14) and late (day 100) to compare differences in acute and chronic rejection, respectively.
Mouse Kidney Transplantation
Orthotopic kidney transplants were performed on the animals as previously described. Briefly, the left kidney of the donor animal was flushed with heparinized saline and removed together with ureter and vessels en mass, including a small (1-2 mm) bladder cuff attached to the distal ureter. The recipient animal underwent a left-sided nephrectomy, and the transplanted kidney was placed orthotopically on day 0. Urinary tract reconstruction was established by either inserting the ureter into the bladder (day 14 experiment only) or suturing the bladder patch to a cystostomy located on the bladder dome 55 (a bladder-to-bladder anastomosis) for survival study and day 100 experiments. All transplanted mice received a single intraperitoneal injection of ampicillin at the time of transplant surgery. No immunosuppressive therapy was administered. The recipient's right native kidney was removed at days 3-7, necessitating the graft to be life-sustaining. Animals with technical graft failure or wound infection became overtly ill (and were euthanized) or died within 4 days of the contralateral nephrectomy and were removed from the study.
Skin Transplantation
Full-thickness tail skin grafts were placed on graft beds prepared on recipients at day 150 after kidney allograft transplantation. Grafts were covered with protective bandages for 7 days. Rejection was defined as graft necrosis of the entire graft area. Recipients that accepted their allograft showed preserved graft size and hair growth.
Blood and Tissue Samples
Blood and kidney tissues were harvested at time of euthanasia. Tissue slices were fixed with 10% neutral-buffered formalin for paraffin embedding, frozen in OCT compound (Sakura Finetek Inc., Torrance, CA), or snap frozen in liquid nitrogen for subsequent mRNA extraction.
Assessment of Kidney Function
Serum creatinine was measured using the modified Jaffe rate reaction by the Biochemistry Department of The Royal Prince Alfred Hospital, Sydney, Australia.
Histology
All histologic analysis was performed in a blinded manner. Periodic acid-Schiff (PAS) staining was performed on 3 mm paraffin kidney sections to assess tubulitis, glomerulosclerosis, and interstitial fibrosis. Tubulitis was examined on 250 tubular cross-sections per animal. Each tubular cross-section was assessed as (1) normal, (2) mild tubulitis (defined as two or three infiltrating mononuclear cells per tubular cross-section and disruption of the basement membrane), or (3) severe tubulitis (defined as greater than or equal to four infiltrating mononuclear cells per tubular cross-section). A score for the degree of tubulitis was calculated for each animal as per a modified method described previously, where each normal tubule was assigned a value of one and the number of tubules affected with mild and severe tubulitis was multiplied by two or three, respectively. The total tubulitis score for each animal was the sum of these figures.
Glomerulosclerosis was quantitated by the presence of PASpositive staining material involving .30% of each glomerulus as described previously. 56 All glomeruli per section were scored to determine the percentage of glomeruli displaying glomerulosclerosis.
Interstitial fibrosis and tubular atrophy were graded using the Banff 97 scoring criteria on a scale of one to three: 1, mild interstitial fibrosis and tubular atrophy (,25% of cortical area); 2, moderate interstitial fibrosis and tubular atrophy (26%-50% of cortical area); 3, severe interstitial fibrosis and tubular atrophy/loss (.50% of cortical area). If changes were minimal but not absent, the score of 0.5 was applied. Using an ocular grid, the score of each sample was counted at splenocytes primed and stimulated with allogeneic cells produced significantly less IL-17 than similarly stimulated WT splenocytes (*P,0.05). Representative data from two independent experiments are presented (mean 6 SD, n=4 or n=8 each).
least in 15-25 consecutive fields across a full section (3200 magnification) and averaged for each graft. Picro-Sirius red (PSR) staining was performed on 5-mm paraffin sections. Interstitial PSR staining area for collagen was assessed by point counting using an ocular grid as described in the work by McWhinnie et al. 57 in at least 12 consecutive fields (3200 magnification). Only interstitial collagen was counted, and vessels and glomeruli were excluded. The result was expressed as the percentage of positive staining area per field.
Immunohistochemisty Staining
Acetone-fixed frozen sections (7 mm) were exposed to 0.06% H 2 O 2 in PBS, blocked with a biotin blocker system (DAKO Corporation), and then blocked in 10% normal horse serum. Primary antibody, rat antimouse CD68 antibody (ABD Serotec), CD4 (BD Biosciences, San Diego, CA), CD8 (BD Biosciences), and hamster anti-mouse CD11c (BD Biosciences) were applied to the sections for 60 minutes. Formalin-fixed paraffin-embedded sections of 5 mm thickness were deparaffinized and boiled for 15 minutes in 10 mM sodium citrate buffer (pH 6.0) for a-SMA (Abcam, MA), HMGB1 (Abcam, MA), and hyaluronan detection. Sections were blocked in 20% normal goat serum and incubated with rabbit anti-a-SMA or anti-HMGB1 for 1 hour. Endogenous peroxidase activity was then quenched in 3% H 2 O 2 in methanol. Concentration-matched Ig was used as an isotype negative control. Sections were incubated with the biotinylated secondary antibody: anti-rat IgG, anti-hamster IgG, or anti-rabbit Ig (BD Biosciences). Instead of a primary antibody, a biotinylated hyaluronan-binding protein (Seikagaku Corp. Japan) at 5 mg/ml was used for hyaluronan staining. Vector stain ABC kit (Vector Laboratories Inc.) was applied to the tissue and followed by 3,39diaminobenzidine substrate-chromogen solution (DAKO, Carpinteria, CA). The slides were counterstained with Harris' hematoxylin.
Quantification of Immunohistochemistry
Analysis of the cellular infiltrates for CD4 and CD8 was performed in a blinded manner by assessing 20 consecutive high-power fields (HPFs; 3400 magnification) of the cortex in each section. Using an ocular grid, the number of cells staining positively for each antibody was counted and expressed as cells per HPF. Analysis of CD68
1 and CD11c 1 infiltrates was performed using a digital image analysis program (Automated Cellular Imaging System ACIS III; Dako, Aliso Viejo, CA). An area of cortex was analyzed for interstitial cellular-positive staining versus counter-stained area. The results were expressed as percentage of positive staining. Analysis of a-SMA staining was assessed by point counting using an ocular grid as described above. Staining around the vessels was not included. 
RNA Extraction and cDNA Synthesis
Total RNA was extracted from kidney tissue and cells using TRIzol (Invitrogen). cDNA was synthesized using oligo d(T) 16 (Applied Biosystems, Foster City, CA) and the SuperScript III Reverse transcription kit (Invitrogen).
Real-Time PCR
Specific Taqman primers and probes for TLR2, TLR4, HMGB1, biglycan, HAS1, HAS2, hsp60, hsp70, IL-6, TNF-a, IL-1b, IL-4, IFNg, CCL2, CXCL10, inducible nitric oxide synthase, and glyceraldehyde-3-phosphate dehydrogenase were previously described. 9, 54, 58 Specific Taqman primers and probes for Granzy meB (Mm00442834_m1), Perforin1 (Mm00812512_m1), TGF-b1 (Mm01178820_m1), IL-17 (Mm00439619_m1), CXCL9 (Mm01345157_m1), MMP2 (Mm00439506_m1), and TIMP1 (Mm01341361_m1) were obtained from Applied Biosystems (Foster City, CA). cDNA was amplified in 13 Universal Master Mix (Applied Biosystems) with gene-specific primers and probes in the Rotor-Gene 6000 system (Corbett Life Science). Data were analyzed using RotorGene 6000 Analysis Software (Corbett Life Science). All results are expressed as ratio to glyceraldehyde-3-phosphate dehydrogenase.
Cell Isolation from Allografts
Cell suspensions from the kidney grafts were isolated as previously described. 56 Kidney cortex was minced and underwent digestion with collagenase and deoxyribonuclease (Sigma-Aldrich); then, they passed through a 250-mm sieve. Cells were collected by centrifugation, resuspended in 40% Percoll (Sigma-Aldrich) in RPMI-1640 medium, and overlayed on a 66.7% Percoll solution. Gradient separation was carried out at 2100 rpm for 20 minutes at room temperature. Spleen and blood cells were also isolated from mice using standard methods.
Flow Cytometric Analysis
Donor-specific alloantibody titers were measured by flow cytometry. Dilutions (1/10 and 1/20) of mouse serum from transplanted mice were incubated with BALB/c (donor) splenocytes for 1 hour at 4°C. After washing three times, the donor cells were incubated with either rat FITC-conjugated anti-mouse IgG1 or IgG2a (BD Biosciences). The median fluorescence intensity of the stained samples was determined by flow cytometry. All analyses were performed on a FACS CALIBUR flow cytometer, and data were analyzed with Cellquest Pro software (BD Biosciences). Results were read as median fluorescent intensity. FITC-conjugated anti-mouse CD4 (clone RM4-5), phycoerythrin (PE)-conjugated anti-mouse IFN-g (clone XMG1.2), PE-Cy7-conjugated anti-mouse CD8 (clone 53-6.7), APC-Cy7-conjugated anti-mouse CD45 (clone 30-F11), and isotype controls were purchased from BD Biosciences. APC-conjugated anti-mouse IL-17A (clone TC11-18H10) was purchased from Biolegend (San Diego, CA), and PE-conjugated anti-mouse FoxP3 (clone FJK-16s) was purchased from eBioscience (San Diego, CA). IFN-g and IL-17A intracytoplasmic stainings were performed after cell incubation with 10 mg/ml PMA and 500 ng/ml ionomycin in the presence of GolgiPlug (BD Biosciences) for 4 hours; then, the cells were stained for surface markers for 40 minutes, washed, fixed with CytoFix/CytoPerm (BD Biosciences), permeabilized with Perm/Wash buffer (BD Biosciences), and labeled with anticytokine antibodies. FoxP3 staining was performed after cell surface marker labeling using eBioscience fixation/ permeabilization and permeabilization buffers according to the manufacturer's instructions. Cytometry analysis was performed on a Canto cytometer using FACS Diva software (BD Biosciences), and data were analyzed with FLOWJO software (Tree Star, Inc).
CD25
+ Cell Depletion In Vitro T Cell Differentiation cells/well to a final volume 100 ml and incubated for 24 hours with 5% CO 2 at 37°C. The plates were washed, and the appropriate biotinylated detection antibody (Mabtech) (diluted to 1 mg/ml in PBS containing 1.5% FCS) was added and incubated overnight at 4°C. After washings, streptavidin-alkaline phosphatase (1:1000) was added for 60 minutes at room temperature. The wells were washed and then developed with filtered substrate solution BCIP/NBT-plus (Mabtech) until distinct spots emerged. Concanavalin A was added to some wells with responder cells only as a positive, technical control; negative control wells with stimulator only and medium only were also performed on each plate. All combinations were performed at least in triplicate. Spots were counted using an automated AID ELISPOT reader (Autoimmun Diagnostika, Strasberg, Germany).
Statistical Analyses
All data are expressed as mean 6 SD. Comparisons between graft survival times were calculated using Kaplan-Meier survival curves with the log-rank test. Statistical differences between the two groups were analyzed by unpaired two-tailed t tests, and multiple groups were compared using one-or two-way ANOVA with posthoc Bonferroni correction (Graph Pad Prism 4.0 software). P values,0.05 were considered significant.
